Trinity Annual Drug Index
Evaluating the Commercial Performance and Impact of Novel Drugs Approved in 2021
Home / Intelligence / Webinars / Trinity Annual Drug Index
White Paper & Webinar:
This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on its commercial performance, therapeutic value and R&D investment.
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by ~18% (7/40) being Autoimmune and 10% (4/40) being Neurology. In this report we describe the notable themes and trends within the industry and take a deeper look at a few products with outstanding performance. Though the impact of the COVID-19 pandemic was primarily felt in 2020, 2021 fared worse than 2020 and sustained an ongoing decline in the relationship between a product’s therapeutic value and its commercial output.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Interested in hearing expert discussion on this white paper?
You will be able to download the white paper through your webinar registration.
Join your choice of 3 webinar sessions:
April 3rd | 12:00-12:45 PM ET
April 8th | 16:00-16:45 UTC+8 – Asia/Shanghai
April 8th | 15:00-15:45 CET – Europe/Berlin
Complete the form below to register for the April 3rd session at 12:00 PM ET
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Complete the form below to register for the April 8th session at 16:00 UTC+8 – Asia/Shanghai
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Complete the form below to register for the April 8th session at 15:00 CET – Europe/Berlin
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Featuring
Related Intelligence
Webinars
Navigating the Early Asset Evaluation Journey with Confidence
Available On Demand
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.
Watch Now
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
Briefs
The “Molecular Optimizer” Archetype: A Strategy for First-Launch Companies to Streamline Their Path to Market
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market. The primary benefit of this approach is that the method offers a higher probability […]
Read More